Johnson & Johnson (JNJ) Upgraded to “Buy” by Vetr

Johnson & Johnson (NYSE:JNJ) was upgraded by stock analysts at Vetr from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday. The firm presently has a $152.28 price target on the stock. Vetr‘s target price points to a potential upside of 7.37% from the stock’s current price.

A number of other equities analysts also recently commented on the company. Credit Suisse Group set a $154.00 price objective on Johnson & Johnson and gave the stock an “outperform” rating in a report on Thursday, October 19th. BMO Capital Markets increased their price objective on Johnson & Johnson to $161.00 and gave the stock an “outperform” rating in a report on Tuesday, December 12th. Zacks Investment Research downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Tuesday, December 12th. Wells Fargo & Co upgraded Johnson & Johnson from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $140.00 to $149.00 in a report on Monday, October 9th. Finally, Stifel Nicolaus increased their price objective on Johnson & Johnson from $140.00 to $142.00 and gave the stock a “hold” rating in a report on Wednesday, October 18th. Four research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $146.01.

Johnson & Johnson (JNJ) traded down $6.31 during trading hours on Tuesday, reaching $141.83. The company had a trading volume of 17,449,593 shares, compared to its average volume of 6,160,000. Johnson & Johnson has a 12-month low of $110.76 and a 12-month high of $148.32. The firm has a market capitalization of $381,030.00, a P/E ratio of 24.62, a P/E/G ratio of 2.76 and a beta of 0.80. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, January 23rd. The company reported $1.74 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.02. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The firm had revenue of $20.20 billion for the quarter, compared to the consensus estimate of $20.08 billion. During the same quarter in the prior year, the company posted $1.58 earnings per share. The firm’s revenue was up 11.5% on a year-over-year basis. equities analysts predict that Johnson & Johnson will post 7.28 earnings per share for the current year.

A number of hedge funds have recently made changes to their positions in the business. Lowe FS lifted its position in Johnson & Johnson by 15.2% in the third quarter. Lowe FS now owns 379 shares of the company’s stock worth $35,000 after purchasing an additional 50 shares during the period. Harding Loevner LP bought a new position in Johnson & Johnson in the second quarter worth $106,000. Americafirst Capital Management LLC bought a new position in Johnson & Johnson in the second quarter worth $101,000. Tuttle Tactical Management LLC bought a new position in Johnson & Johnson in the second quarter worth $103,000. Finally, Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its position in Johnson & Johnson by 29.9% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares during the period. Institutional investors own 65.72% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/23/johnson-johnson-jnj-upgraded-to-buy-by-vetr.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply